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Abstract
Background: Fragile X syndrome (FXS) is considered the most common cause of inherited
mental retardation. Affected people have mental impairment that can include Attention Deficit and/
or Hyperactivity Disorder (ADHD), autism disorder, and speech and behavioural disorders.
Several pharmacological interventions have been proposed to treat those impairments.
Methods: Systematic review of the literature and summary of the evidence from clinical controlled
trials that compared at least one pharmacological treatment with placebo or other treatment in
individuals with diagnosis of FXS syndrome and assessed the efficacy and/or safety of the
treatments. Studies were identified by a search of PubMed, EMBASE and the Cochrane Databases
using the terms fragile X and treatment. Risk of bias of the studies was assessed by using the
Cochrane Collaboration criteria.
Results: The search identified 276 potential articles and 14 studies satisfied inclusion criteria. Of
these, 10 studies on folic acid (9 with crossover design, only 1 of them with good methodological
quality and low risk of bias) did not find in general significant improvements. A small sample size
trial assessed dextroamphetamine and methylphenidate in patients with an additional diagnosis of
ADHD and found some improvements in those taking methylphenidate, but the length of follow-
up was too short. Two studies on L-acetylcarnitine, showed positive effects and no side effects in
patients with an additional diagnosis of ADHD. Finally, one study on patients with an additional
diagnosis of autism assessed ampakine compound CX516 and found no significant differences
between treatment and placebo. Regarding safety, none of the studies that assessed that area found
relevant side effects, but the number of patients included was too small to detect side effects with
low incidence.
Conclusion:  Currently there is no robust evidence to support recommendations on
pharmacological treatments in patients with FXS in general or in those with an additional diagnosis
of ADHD or autism.
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Background
Fragile X syndrome, caused by a large expansion of a CGG
trinucleotide repeat within the FMR1 gene located on
chromosome X (q27.3) [1], is considered the most com-
mon cause of inherited mental retardation. It has been
estimated that FXS syndrome affects approximately 1 in
4,000 males and 1 in 8,000 females [2]. However those
estimates are based on population projections from
cohorts of children with special education needs and thus
they could underestimate the extent of clinical involve-
ment as some individuals affected by the behavioural,
emotional and/or learning disabilities of FXS could have
IQs in the normal or borderline range [3,4].
People with FXS have mental dysfunction that normally
includes some degree of mental retardation, ranging from
severe to mild. The dysfunction can also include Attention
Deficit and/or Hyperactivity Disorder (ADHD) [5,6],
autism disorder or the autism spectrum disorder [7,8] and
speech and behavioural disorders, such as anxiety-related
symptoms including Obsessive Compulsive Disorder-like
and perseverative behaviours, emotional lability and
aggressive or self-aggressive behaviours.
The rationale underlying pharmacological treatments in
persons with FXS is diverse and it has been extensively
covered elsewhere [9-11]. After the discovery of FXS it was
observed that chromosomes from people with fragile X
needed to be cultured in solutions deficient in folic acid in
order to reveal the defect and it was thought that maybe
individuals with fragile X syndrome had a lack of folic
acid in their bodies, or were unable to make optimal use
of the folic acid they had. Therefore, it was argued that
supplementing their dietary intake might remediate
adverse developmental and behavioural effects of the con-
dition and the first therapeutic trials focussed primarily
on folic acid. More recently, pharmacological treatment
strategies have been focussed mainly as supportive strate-
gies designed to maximize social functioning. As behav-
iour in FXS can significantly impact functionality,
symptom-based treatment of the most problematic
behaviours in the individual with FXS can be quite helpful
[12]. As many people with FXS had additional diagnosis
of ADHD, stimulants like methylphenidate and dex-
troamphetamine-already efficacious in non FXS patients-
have been assessed in people affected with FXS. In order
to avoid some of the side effects observed in treatment
with stimulants other researchers looked for a non-stimu-
lant pharmacological treatment for ADHD symptoms in
people with FXS and tested L-acetylcarnitine, a product
that had been shown to inhibit in vitro the cytogenetic
expression of the FXS-associated fragile site FRAXA [13].
CX 156, an AMPA receptor-positive modulator has been
evaluated to study its effects on cognitive disability in peo-
ple with FXS, given that recent understanding of defects in
synaptic plasticity in the fmr1 knock-out KO mouse had
led to the proposal of several pharmacological targets in
FXS to attempt to normalize synaptic connectivity, includ-
ing AMPA receptor activation [14].
To our knowledge, while several recently published arti-
cles include narrative reviews of this topic [10-12,15,16],
to date no comprehensive systematic review of the safety
and efficacy of pharmacological interventions in people
with FXS has been published.
Methods
Objective
To systematically review the evidence on the efficacy and
safety of pharmacotherapy in the treatment of people with
FXS.
Inclusion criteria
We included all Clinical Controlled Trials (CCTs), rand-
omized or not, that fulfil all the following criteria: (i)
compared at least one pharmacological treatment with
placebo or other treatment, (ii) included people with a
diagnosis of FXS, (iii) assessed efficacy and/or safety of the
treatments, and (iv) included as a main outcome results
on psychological and social performance measured by
standardized or validated scales.
Studies that assessed the impact of different medications
in people with fragile X pre-mutation related syndromes,
such as Fragile X-associated tremor/ataxia syndrome
(FXTAS) or premature ovarian failure, were not included
here.
Search strategies
Electronic searches were performed in PubMed using
"fragile X AND treatment" text words and the following
limits: "Humans, Clinical Trial, Meta-Analysis, Practice
Guideline, Randomized Controlled Trial, Review", with-
out language restriction. EMBASE was searched via Ovid
SP using "fragile X AND treatment" text words and limited
to studies in humans. CENTRAL and the other Cochrane
Library databases were searched using "fragile X" text
words. The electronic searches were closed in March 2009
and complemented with reference lists from the trials and
reviews retrieved. Two reviewers screened each abstract
and decided which studies fulfilled the inclusion criteria.
Outcomes selected
For the purpose of this review only outcomes measured by
standardized instruments, regarding safety for the patients
and clinical efficacy were taken into account. For efficacy,
outcome domains included are those related with intelli-
gence and behavioural, emotional and/or learning capa-
bilities.BMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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Certain measures like percentages of fragile X cells or
folate levels in the blood, were assessed in some CCTs, but
will not be presented here due to their unclear clinical
implications.
Data extraction and evaluation of methodological quality 
of the studies
Data on the main characteristics of the clinical trials
included in this review were extracted independently by 2
reviewers, disagreements being solved by consensus.
Methodological quality of the studies was assessed using
the Cochrane Collaboration's criteria [17], including the
following domains to assess the risk of bias: allocation
sequence generation; allocation concealment; blinding of
participants, personnel and assessors; incomplete out-
come data; selective outcome reporting.
Statistical methods
Even though the initial intention was to perform a statis-
tical integration of the results when there was more than
one study on any specific drug and outcome, this was pre-
cluded by clinical heterogeneity of the populations, scar-
city of numerical data and the huge variability of outcome
measures reported among studies.
Results
Literature search
The literature searches identified a total of 383 documents
which was reduced to 276 after removing duplicates. After
screening the abstracts, 16 full text documents were
retrieved and assessed. Two studies were obtained from
the text and references of other studies. One CCT study on
folic acid, published only as an abstract for a professional
meeting, was not included in this review due to absence of
data concerning results [18]. Another study that assessed
the effects of propanolol on stereotyped behaviours in a
single person was considered as a case study, not a CCT
[19]. Finally, 14 studies fulfilled the criteria for inclusion.
More detailed information is given in figure 1, where the
QUORUM flow diagram [20] is presented.
Bibliographic review Figure 1
Bibliographic review. Flow diagram.
Potentially relevant documents identified and screened 
for retrieval n = 383; after removing duplicates n = 276 
PubMed (193), EMBASE (125), Cochrane Central 
Register of Controlled Trials (21), other Cochrane 
Library databases (23)
Papers excluded due to abstract screening  
Non CCT: n = 260 
Potentially appropriate CCTs to be included in the 
systematic review  
n=16 
CCT with usable information n = 14 
- folic acid n = 10 
- stimulants n = 1 
- L-Acetylcarnitine n = 2 
- Ampakine compound CX516 n = 1 
Papers excluded due to full text screening  
n = 2 
- No CCT: n = 1 
- No information available on results n = 1 
Published until 7/03/2009 
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Efficacy and safety of pharmaceutical interventions
In the following sections, results and discussion will be
presented separately for the different interventions. Tables
1, 2 and 3 present the information regarding the main
characteristics of trials and main results.
Folic acid
We found 10 published CCTs that assessed the efficacy
and safety of folic acid treatment in people with FXS. The
first studies were published in 1983 and the last one in
1992. Seven of the studies were performed in the USA [21-
27], one in Canada [28], one in Germany [29] and one in
Sweden [30].
The number of participants in the studies was in general
very small, ranging from two to 25 individuals, including
overall 82 people. All these participants in the studies
were male and their ages ranged from 1.5 to 54 years. The
degree of mental retardation varied from borderline to
severe and four studies included patients with an addi-
tional diagnosis of autism or autistic behaviour [22-
24,30,31]. Just one study was performed on an in-patient
basis [21] and the duration of the follow-up in the studies
ranged from sixteen days to twelve months.
Doses of folic acid varied, ranging from 5 mg/day to 250
mg/day, 10 mg/day being the most commonly used dos-
age, as presented in six of the studies. Nine of the studies
used placebo as the control intervention and one study
used a control preparation with a dose less than 0.0015
mg/day of folic acid [29].
None of the trials presented a parallel design. Nine of the
ten studies were crossovers and in one study all patients
took placebo first and then folic acid [26].
In five of the clinical trials the order of medications was
randomised, but only one of them is known to have used
an acceptable method of randomisation [25]. In fact, the
method of randomisation was not stated in the other four
reports [21,24,27,29]. Only one study could be classified
as being of overall good methodological quality and low
risk of bias [25].
Overall, the studies did not find significant improvement
in outcomes assessed in periods taking folic acid com-
pared to placebo. Only one study found a statistically sig-
nificant improvement in an outcome variable in the
period of folic acid treatment but this was found in a sub-
group of eight patients (improvement of IQ in prepuberal
children) [25].
The study in which all patients had an additional diagno-
sis of autism included only four patients and did not find
significant differences between folic acid and placebo in
the assessed outcomes; in particular, mean scores of the
Autism Behaviour Checklist did not differ significantly
between placebo and folic acid periods [30]. Two other
studies that included some patients with an additional
diagnosis of autism showed some improvements meas-
ured by the Autistic Descriptors Checklist, but they did
not carry out statistical analysis [22,24]. Another study
included two patients with an additional diagnosis of
autistic behaviour, but did not provide separate data on
them [23]. Overall the quality of reporting of quantitative
data was poor and did not allow us to extract reliable
effect sizes.
Regarding safety only two of the studies reported on side
effects; one of them found no side effects [21] and the
other found only minor transient side effects [27].
Dextroamphetamine and methylphenidate
One crossover, randomised, double blind trial assessed
the efficacy of dextroamphetamine and methylphenidate
versus placebo in 15 children, two of them women, with
FXS and an additional diagnosis of Attention Deficit
Hyperactivity Disorder (ADHD) [5]. The length of the fol-
low-up was three weeks, but each intervention lasted only
one week. The authors reported that, compared to pla-
cebo, there was a clinical response in two thirds of
patients, but no statistically significant difference between
amphetamine and placebo for any of the ADHD meas-
ures, except for the improvement seen on the ACTeRS
scale completed by the teacher. However, the article does
not present enough data to calculate appropriate effect
sizes. The social skills factor and improvements in atten-
tion were significantly better with methylphenidate
(mostly in mildly retarded individuals) but not with
amphetamine. Significantly more side effects appeared
while taking amphetamine, mainly mood lability and irri-
tability.
L-Acetylcarnitine (LAC)
Two double-blind trials have assessed the safety and effi-
cacy of LAC in boys with FXS and an additional diagnosis
of ADHD [13,32]. Both of these were randomised pla-
cebo-controlled and used a parallel design.
The first study included 20 patients and compared LAC, in
a dose of 100 mg/kg/day versus placebo, and found no
significant difference between LAC and placebo on the
Wechsler Scale or in the Bender Gestalt test and Conners'
questionnaire completed by teachers. However, the Con-
ners' Abbreviated Parent-Teacher questionnaire com-
pleted by parents showed a significant reduction (Hedges
g effect size = -3.94; SE = 0.91) of hyperactive behaviour at
the end of the study in the LAC-treated subjects [32].
The second study, classified by the authors as a Phase II
study, involving eight centres in three European countries,
compared LAC, at doses of 20-50 mg/kg/day versus pla-BMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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Table 1: Characteristics of studies
Folic acid (FA)
Reference Participants and Follow-Up Period Methods Interventions
Brown 1984 [21] N = 2 brothers, 10.5 and 18.8 years. 
Setting: in-patients. FUP: 16 days
R, CO, DB. AASG: no; AAC: 
unclear; AB: unclear; IDAA: yes; 
FSR: yes.
FA 1,6 mg/kg intravenous vs Placebo
Brown 1986 [22] N = 5 males, 8 to 26 years. 3 autism FUP: 
9 months
R, CO, DB. AASG: unclear; AAC: 
unclear; AB: unclear; IDAA: yes; 
FSR: yes.
FA 250 mg/day vs Placebo
Carpenter 1983 [23] N = 4 males, 2 to 10 years. IQs: 45 to 
50. 2 autistic behaviour. FUP: 6 months
NR, CO, DB. AASG: no; AAC: 
unclear; AB: unclear; IDAA: 
unclear; FSR: unclear.
FA 10 mg/day vs Placebo
Fisch 1988 [24] N = 6 males, 3.5 to 15 years. 3 autistic, 3 
mental retardation only (borderline to 
severe). FUP: 12 months
R, CO, DB, SA. AASG: unclear; 
AAC: unclear; AB: unclear; IDAA: 
yes; FSR: yes.
FA 10 mg/day vs Placebo
Froster-Iskenius 1986 [29] N = 10 males, 15 to 54 years. IQ: 21 to 
60. FUP: 4 months
R, P, DB. AASG: unclear; AAC: 
unclear; AB: no; IDAA: yes; FSR: 
yes.
FA 10 mg/day vs 0.0015 mg of folic 
acid/day, 2 months and 2 months 
with folic acid, 10 mg/day
Gillberg 1986 [30] N = 4 males, 6 to 14 years. IQ: 39 to 64. 
All autism, 3 epilepsy. FUP: 9 months
NR, CO, DB, SA. AASG: no; AAC: 
unclear; AB: unclear; IDAA: yes; 
FSR: yes.
FA 5 mg/day vs Placebo
Hagerman 1986 [25] N = 25 males, 1 to 31 years. IQ: 39 to 
82. Many of the younger ones in special 
education program with language and 
occupational therapy. Many adults use 
phenothiazines. FUP: 12 months
R, CO, DB, SA. AASG: yes; AAC: 
unclear; AB: yes; IDAA: yes; FSR: 
yes.
FA 10 mg/day vs Placebo
Madison 1986 [26] N = 3 males, 3, 8 and 12 years old.
Moderate mental retardation. FUP: 11 
weeks
NR, DB. AASG: no; AAC: unclear; 
AB: unclear; IDAA: yes; FSR: yes.
No drug-no placebo (20 days). 
Placebo (13-45 days). Folic acid 10 
mg/day (10-43 days)
Rosenblatt 1985 [28] N = 2 monozygous male twins, 14 years 
old, mentally retarded. FU: 12 months
NR, CO. AASG: no; AAC: unclear; 
AB: unclear; IDAA: yes; FSR: yes.
FA 5 mg/day vs Placebo
Strom 1992 [27] N = 21 males, 2-22 years, mean 8.3 
years. FUP: 24 weeks
R, CO, DB, SA. AASG: unclear; 
AAC: unclear; AB: unclear; IDAA: 
yes; FSR: yes.
FA 15 mg/day vs Placebo
Ampakine compound CX516
Berry-Kravis 2006 [14] N = 49. 11 female, 18-49 years. IQ: 36 
to75, mean 43; 12 ≥50. Autism 21, 
spectrum: 4. 27 on psychoactive 
medication. FUP: 4 weeks
Phase II, R, P, DB, SA. AASG: yes; 
AAC: yes; AB: yes; IDAA: yes; FSR: 
yes.
Ampakine compound CX516 600-
900 mg/day vs Placebo
Dextroamphetamine 
Methylphenidate
Hagerman 1988 [5] N = 15, 2 female. 3.8-11.8 years. IQ: 29 
to 77 (3 IQ >70). All attentional 
problems. 40% on stimulants. FUP: 3 
weeks
R, CO, DB, SA. AASG: unclear; 
AAC: unclear; AB: yes; IDAA: yes; 
FSR: yes.
Dextroamphetamine
2 mg/kg/day vs Methylphenidate 0.6 
mg/kg/day vs PlaceboBMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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cebo, in 63 patients [13]. All the patients received extra
care and stimulation both at school and at home, and
made regular visits to neuropsychiatrists who prompted a
revision of the support activities that children received
(speech therapy, physical therapy, occupational therapy,
or other modality). The authors report that both groups
improved their behaviour, showing that psychosocial
intervention has a significant therapeutic effect. Statisti-
cally significant stronger reduction of hyperactivity and
improvement of social behaviour was observed in
patients treated with LAC, compared with the placebo
group, on Conners' Global Index-Parents (CGI-P)
(Hedges g effect size = -0.30; SE = 0.28) and Vineland
Adaptive Behavior Scales - Survey Form (VABS) (Hedges g
= 0.52 and 0.65; SE = 0.29 and 0.29). They also reported
no significant side-effects in LAC group.
Ampakine compound CX516
One phase II parallel, randomised, double-blind, pla-
cebo-controlled clinical trial of four weeks of duration,
assessed efficacy and safety of ampakine compound
CX516 versus placebo in 49 people with FXS, 27 of them
taking concomitant psychoactive medication [14]. Twenty
one patients had an additional diagnosis of autism and
four of autism spectrum.
This study found no significant improvement in memory,
the primary outcome measure, or in secondary measures
of language, attention/executive function, behaviour, and
overall functioning in CX516-treated subjects compared
to placebo. There were minimal side effects, no significant
changes in safety parameters, and no serious adverse
events.
Discussion
In this systematic review we have not found reliable and
solid evidence to support the recommendation of any spe-
cific medication for people with FXS. There are different
reasons to justify this conclusion. Some reasons apply to
all the treatments studied and others apply only to a spe-
cific intervention.
It is general the problem related with the small sample
sizes of the studies, which can result in problems in two
areas: increased probability of type 2 errors (positive
effects found in some studies could have been statistically
significant if the samples had been larger) and inadequate
size to detect side effects with low incidence. It is also
striking the fact that very few women have been included
in the studies, which probably can be explained by the
previously extended belief that the disease was a problem
only in males. In relation to the small numbers of
patients, and also to the scarcity of studies, it must be
taken into account that FXS is a relatively new disease, the
specific genetic mutation was identified in 1991, and that
its prevalence is low, being included into the category of
the so-called "rare diseases". It is understandable that few
research groups, and with limited resources, have been
willing and able to carry out clinical trials on people with
FXS. It also takes time until research from animal models
is translated to assessment in human beings [33].
Regarding to the design of the studies and the assessment
of their potential risk of bias, only a few of them could be
classified as being of acceptable or good methodological
quality, although it must be taken into account that only
two studies were published after the CONSORT statement
on standards for reporting trials [34]. Indeed, many of the
publications provide insufficient information to allow
critical assessment of the methodological quality of the
trials and proper evaluation of the risk of bias. So it is dif-
ficult to know whether a particular study is methodologi-
cally flawed in the design or whether the reporting of the
methods is incomplete.
Concerning specifically folic acid, it must be taken into
account that apart from one study [26] the trials that
assessed folic acid versus placebo were crossover studies
and that the possibility of a 'carry-over' of treatment effect
from one period to the next cannot be discarded. A carry-
over effect means that the observed difference between the
treatments depends upon the order in which they were
received; hence the estimated overall treatment effect will
L-Acetylcarnitine
Torrioli 1999 [32] N = 20 males, 6-13 years. IQ:30 to 69
Hyperactive behaviour. FUP: 12 months
R, P, DB, SA. AASG: unclear; AAC: 
unclear; AB: unclear; IDAA: 
unclear; FSR: yes.
L-Acetylcarnitine 100 mg/kg/day vs 
Placebo
Torrioli 2008 [13] N = 63 males, 6-13 years, all with 
Attention Deficit Hyperactivity 
Disorder. All extra care and stimulation 
at school and home, and visits by 
neuropsychiatrists. FUP: 12 months
Phase II, R, P, DB, SA. AASG: 
unclear; AAC: unclear; AB: unclear; 
IDAA: yes; FSR: yes.
L-Acetylcarnitine
20-50 mg/kg/day vs Placebo
* AAC: adequate allocation concealment; AASG: adequate allocation sequence generation; AB: adequate blinding of participants, personnel and 
assessors; CO: crossover; DB: double blind; FSR: free of selective outcome reporting; FUP: follow up period; IDAA: incomplete data adequately 
addressed; N: number of patients; NR: non randomized; P: parallel; R: randomized; SA: statistical analysis presented.
Table 1: Characteristics of studies (Continued)BMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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Table 2: Outcome measures and main results of studies on folic acid
Reference Measures of interest: assessment method Main Results
Brown 1984 [21] Psychological: Stanford-Binet, Peabody Picture Vocabulary Test 
Revised (PPVTR) Leither International Performance Scale of 
non-verbal performance. Scoring by researchers and parents for 
eye contact, appropriate social smiling, communicative speech 
and hyperventilating.
Stanford Binet IQ scores did not change 
significantly. PPVT-R scores appeared unrelated to 
folic acid treatment. Leither test of non-verbal 
performance showed improvement in one subject, 
from 3.0 to 5.6, but not in the other (no more 
details in article). Statistical testing not presented.
Safety: no side effects.
Brown 1986 [22] Leiter or Wechsler IQ tests. Autistic Descriptors Checklist 
(ADC): parental reporting rating checklist. Alpern-Ball test.
Changes of performance ratings not correlated 
with treatment. Pooled data not provided, only 
person by person. Statistical testing not presented.
Safety: nothing reported.
Carpenter 1983 [23] Psychological, speech and language, and psychiatric evaluations 
but not specified.
No measurable improvement in speech, language 
or intellectual abilities were found during therapy. 
Numeric data not provided. Statistical testing not 
presented.
Safety: nothing reported.
Note: Data from abstract.
Fisch 1988 [24] Autistic Descriptors Checklist (ADC). Vineland Adaptative 
Behaviour Scale (VABS).
No statistically significant improvements in periods 
of folic acid treatment, neither in prepubescent nor 
in adolescent patients. Pooled data not provided, 
only person by person.
Safety: nothing reported.
Froster-Iskenius 1986 [29] Coloured Progressive Matrices test (CPM). Test for fine motor 
co-ordination, concentration and comprehension.
No improvement in concentration, fine motor co-
ordination or comprehension in adults, but may 
have some effect in children. Pooled data not 
provided, only person by person. Statistical testing 
not presented.
Safety: nothing reported.
Gillberg 1986 [30] Autism Behaviour Checklist (ABC) and other checklist 
questionnaires pertaining to autism developed by authors. 
Parents "unstructured" diaries on child overall behaviour and 
language skills.
Mean ABC scores did not differ in a statistically 
significant way between placebo and folic acid 
periods. Numerical detailed information not 
provided.
Safety: nothing reported.
Hagerman 1986 [25] Speech and language testing: Peabody Picture Vocabulary Test 
(PPVT), Test of Language Development (TOLD) and an apraxia 
battery. Psychological testing: Yale Revised Developmental 
Schedules, Stanford-Binet, Leiter International Scale. Behavioural 
assessments: Autism Behavior Checklist (ABC) of the Autism 
Screening Instrument for Educational Planning (ASIEP) and the 
Childhood Autism Rating Scale (CARS).
No statistical differences (Wilcoson Rank Sum 
Test) between placebo and folic acid in: change in 
IQ, language (PPVT, TOLD, apraxia battery) 
behavioural areas, CARS, ABC.
Psychological testing: IQ scores statistically 
significant improvement in prepuberal males while 
being treated with folic acid (one tailed p = 0.014; 
two tailed p = 0.028).
Safety: nothing reported.
Madison 1986 [26] Memory skills: Automated Device for the Assessment of 
Memory (ADAM); Verbal recall of objects and number series. 
Compliance and behavioural appropriateness.
No evident change in memory skills, compliance 
and behavioural appropriateness during treatment 
phase. Pooled data not provided, only person by 
person. Statistical testing not presented.
Safety: nothing reported.BMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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be affected (usually underestimated, leading to a bias
towards the null) [35]. One study showed positive statis-
tically significant results on IQ measurements in a small
group of 8 prepuberal children, but not in older patients
[25]. In younger children it cannot be discarded that nor-
mal neuro-developmental changes could explain impres-
sive improvements in some children in periods of time as
short as six months; and in that study most of the children
with the largest positive effects also had significant
improvements in the placebo phase.
Regarding stimulants, the only RCT that assessed their
effect in 15 children with FXS also diagnosed with ADHD
[5] found some positive effects of metylphenidate, but it
can only be considered as an exploratory study due to the
very short length of the treatment -one week-, the small
sample size and the crossover design with lack of wash-
out period between treatments.
In relation to L-acetylcarnitine (LAC) a recently published
study in children with FXS also diagnosed with ADHD
was classified by the authors as a phase II study [13]. They
found statistically significant stronger reductions of
hyperactivity and improvement of social behaviour in
patients treated with LAC, compared with the placebo
group, as assessed by Conners' Global Index-Parents
(CGI-P) and Vineland Adaptive Behavior Scales - Survey
Form (VABS). LAC doses in that study ranged from 20 to
50 mg/kg/day. A previous smaller study carried out by the
same research group assessed LAC at a much higher dose,
100 mg/kg/day and found significant statistical differ-
ences in favour of LAC in Conners' Abbreviated question-
naire for parents, but not for teachers [32]. Even though it
is difficult to put value on the impact in the quality of life
and social or intellectual performance of affected children
of changes in scales assessed in a subjective way [31,36],
the positive results observed with LAC merit replication,
with appropriate samples sizes in children with FXS and
ADHD, since no significant side-effects in the LAC group
were reported.
However the mechanisms underlying the pathogenesis of
FXS still remain unclear and the wide variety of treatments
under evaluation probably reflects a lack of a single under-
lying pharmacological mechanism for the several impair-
ments and symptoms associated with FXS. Several other
medications (e.g., fenobam, lithium, aricept, memantine)
that have been evaluated in open-label non comparative
studies are now possible candidates for clinical controlled
trials [11,37-40]. Other products (e.g. minocycline, alpha-
tocopherol, melatonin) that have been being tested
recently in animal models could open new prospects for
future treatments [41-43].
Nevertheless given that intellectual, behavioural, emo-
tional and/or learning performance in people with FXS is
strongly influenced by different social factors, pharmaco-
logical treatments must be understood and assessed in the
context of other interventions being in place. Often pro-
posed areas of non pharmacological interventions include
modifications in the home environment, more-tailored
behavioural interventions and classroom environments,
language and occupational therapy, and attention to
social factors. Unfortunately, as a recent review points out,
few studies have been published on the effectiveness of
behavioural or social interventions among patients with
FXS [11,44-46]. So it is advisable to promote studies that
assess the effect of combined pharmacological and non-
pharmacological interventions. In particular, it should be
tested whether combined treatments could be more ben-
eficial if administered in the early years in children with
FXS.
Compared to previous reviews on pharmacological inter-
ventions on FXS, this review is the first one done follow-
ing standardized methodology for systematic reviews. It
Rosenblatt 1985 [28] Wechsler Intelligence Scale for Children-Revised (WISC-R) 
Peabody Picture Vocabulary Test Form M (PPVT), Goodenough-
Harris Drawing Test (G-H), Rey Children's Word List, Token 
Test of Auditory Comprehension, Producing Names on 
Confrontation (test 8 of Clinical Evaluation of Language 
functioning (CELF), Boston Naming Test, Developmental Test of 
Visual-Motor integration (DTVMI), Wide Range Achievement 
Test (WRAT), reading Comprehension (Barnell Loft Multiple 
Skills Series Al) and Domino Pattern Counting Task. Parent's 
Questionnaire, Teacher Behavior Checklist and a Checklist of 
Problem Behaviors.
Strom 1992 [27] Cognitive function and behavioural level: Vineland Adaptive 
Behavioral Scales, Peabody Picture Vocabulary Test-Revised 
(PPVT-R), Conners' Parent and Teaching Rating Scales, the 
ADD-H: Comprehensive Teacher's Rating Scales (ACTeRS), and 
a questionnaire designed by the researchers
No statistically significant differences between the 
folic acid and placebo phases of the study in any 
outcome measurement instrument: Vineland (51.0 
vs 50.9); PPVT-R (55.4 vs 59.2), Conners' (15.5 vs 
13.4).
Safety: minor side effects (transient problems with 
diarrhea, sleep delays, mood swings.
Table 2: Outcome measures and main results of studies on folic acid (Continued)BMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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Table 3: Outcome measures and main results of studies not on folic acid
Ampakine compound CX516
Reference Measures of interest: assessment method Main Results
Berry-Kravis 2006 [14] Primary outcome, memory domain: Visual Memory 
and Visual Sequential Memory Subtests of the Test of 
Visual--Perceptual Skills (TVPS), the Memory for 
Words Subtest of the Woodcock-Johnson Tests of 
Cognitive Ability--Revised and the Repeatable Battery 
for the Assessment of the Neuropsychological Status 
(RBANS).
Secondary outcome measures. Attention/Executive 
Function Domain: SNAP IV. Language Domain: 
Peabody Picture Vocabulary Test-III, Forms A and B 
(PPVT-III) or the Clinical Evaluation of Language 
Fundamentals-3 (CELF-3). Behavioral Domain: Autism 
Diagnostic Observation Scale (ADOS), the Gilliam 
Autism Rating Scale (GARS), the Childhood Autism 
Rating Scale (CARS), a clinician-rated scale to evaluate 
modification of autistic features, the ABC-C, and the 
behaviour component of CGI - Improvement (CGI-I) 
and VAS. Clinical Cognitive Improvement Measures: 
VAS (caregiver rated) for cognition and the subject's 
chosen task (described above) and CGI-I (clinician 
rated) for cognition and the task.
Adverse events: Aberrant Behavior Checklist - 
Community Edition (ABC-C).
Wilkoson rank-sum test performed. No significant 
improvement in memory, the primary outcome measure, or in 
secondary measures of language, attention/executive function, 
behaviour, and overall functioning in CX516-treated subjects 
compared to placebo.
There were minimal side effects, no significant changes in safety 
parameters, and no serious adverse events. There was a 12.5% 
frequency of allergic rash in the CX516 group and 1 subject 
developed a substantial rash.
Dextroamphetamine Methylphenidate
Reference Measures of interest: assessment method Main Results
Hagerman 1988 [5] Conners' Abbreviated Parent-Teacher Questionnaire. 
ADDH: Comprehensive Teacher Rating Scale 
(ACTeRS). Behavioural observation. Measure of 
movement: Large scale integrated sensor actometer 
(LSI). Delay task. Vigilance task.
Paired t tests performed. Compare to placebo clinical response 
in two thirds of patients, but no statistically significant difference 
between amphetamine and placebo for any of the ADHD 
measures, except for the improvement seen on the ACTeRS 
scale completed by the teacher. Social skills factor and 
improvements in attention significantly better with 
methylphenidate (mostly in mildly retarded persons) but not 
with amphetamine.
Safety: significantly more side effects while taking amphetamine, 
mainly mood lability and irritability.
L-Acetylcarnitine
Reference Measures of interest: assessment method Main Results
Torrioli 1999 [32] Wechsler Intelligence Scale for Children-Revised 
(WISC-R); the Bender Gestalt test; and the Conners' 
Abbreviated Parent-Teacher Questionnaire.
Non-parametric Wilcoson independent-sample test performed. 
No statistically significant difference between L-Acetylcarnitine 
and placebo in Wechsler Scale and Bender Gestalt tests and 
Conners' questionnaire completed by teachers. The Conners' 
Abbreviated Parent questionnaire showed a significant 
reduction (P = 0.0065) of hyperactive behaviour at one year in 
the LAC-treated subjects.
Safety: no side effects noted in LAC group.
Torrioli 2008
[13]
Conners' Global Index-Parents (CGI-P) and Conners' 
Global Index-Teachers (CGI-T).
Vineland Adaptive Behavior Scales-Survey Form 
(VABS) to evaluate adaptive behaviour, four domains: 
communication, daily living skills, socialization, and 
motor skills.
Wechsler Intelligence Scale for Children-Revised 
(WISC-R).
Side effects.
T tests and repeated measures multivariate analysis using the 
general linear model were performed. Statistically significant 
stronger reduction of hyperactivity and improvement of social 
behaviour in patients treated with LAC, compared with the 
placebo group, in CGI-P y VABS. Both groups improved their 
behaviour, showing that psychosocial intervention has a 
significant therapeutic effect.
Safety: no side effects in LAC group.BMC Neurology 2009, 9:53 http://www.biomedcentral.com/1471-2377/9/53
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also provides readers with complete data on the main
characteristics of the studies, including aspects relating
with their methodological quality, and their results.
Conclusion
There is no robust evidence to support recommendations
on pharmacological treatments in people with FXS in gen-
eral or in those with an additional diagnosis of ADHD or
autism. Available data are insufficient to draw firm con-
clusions or to make recommendations. Some positive
results found in various studies should be confirmed by
further parallel randomised trials, properly designed and
with adequate statistical power, before these treatments
could be translated to standard medical practice. New tri-
als should include affected women and test whether phar-
macological treatments could be more beneficial if
administered in the early years in affected children, either
alone or combined with non-pharmacological interven-
tions.
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